Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Epidermal-specific deletion of CD44 reveals a function in keratinocytes in response to mechanical stress.

Shatirishvili M, Burk AS, Franz CM, Pace G, Kastilan T, Breuhahn K, Hinterseer E, Dierich A, Bakiri L, Wagner EF, Ponta H, Hartmann TN, Tanaka M, Orian-Rousseau V.

Cell Death Dis. 2016 Nov 10;7(11):e2461. doi: 10.1038/cddis.2016.342.

2.

Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.

Matzke-Ogi A, Jannasch K, Shatirishvili M, Fuchs B, Chiblak S, Morton J, Tawk B, Lindner T, Sansom O, Alves F, Warth A, Schwager C, Mier W, Kleeff J, Ponta H, Abdollahi A, Orian-Rousseau V.

Gastroenterology. 2016 Feb;150(2):513-25.e10. doi: 10.1053/j.gastro.2015.10.020. Epub 2015 Oct 24.

PMID:
26597578
3.

Perspectives of CD44 targeting therapies.

Orian-Rousseau V, Ponta H.

Arch Toxicol. 2015 Jan;89(1):3-14. doi: 10.1007/s00204-014-1424-2. Epub 2014 Dec 5. Review.

PMID:
25472903
4.

c-Met recruits ICAM-1 as a coreceptor to compensate for the loss of CD44 in Cd44 null mice.

Olaku V, Matzke A, Mitchell C, Hasenauer S, Sakkaravarthi A, Pace G, Ponta H, Orian-Rousseau V.

Mol Biol Cell. 2011 Aug 1;22(15):2777-86. doi: 10.1091/mbc.E11-02-0134. Epub 2011 Jun 16.

5.

A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis.

Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, Christofori G, Héroult M, Augustin HG, Ponta H, Orian-Rousseau V.

Blood. 2009 Dec 10;114(25):5236-44. doi: 10.1182/blood-2009-04-219204.

6.

Adhesion proteins meet receptors: a common theme?

Orian-Rousseau V, Ponta H.

Adv Cancer Res. 2008;101:63-92. doi: 10.1016/S0065-230X(08)00404-1. Review.

PMID:
19055943
7.

Haploinsufficiency of c-Met in cd44-/- mice identifies a collaboration of CD44 and c-Met in vivo.

Matzke A, Sargsyan V, Holtmann B, Aramuni G, Asan E, Sendtner M, Pace G, Howells N, Zhang W, Ponta H, Orian-Rousseau V.

Mol Cell Biol. 2007 Dec;27(24):8797-806. Epub 2007 Oct 8.

8.

Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac.

Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P.

Cancer Res. 2007 Jan 15;67(2):520-7.

9.

Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin.

Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P, Ponta H.

Mol Biol Cell. 2007 Jan;18(1):76-83. Epub 2006 Oct 25.

10.

A five-amino-acid peptide blocks Met- and Ron-dependent cell migration.

Matzke A, Herrlich P, Ponta H, Orian-Rousseau V.

Cancer Res. 2005 Jul 15;65(14):6105-10.

11.

Genes upregulated in a metastasizing human colon carcinoma cell line.

Orian-Rousseau V, Mink S, Mengwasser J, HogenEsch H, Guo F, Thies WG, Hofmann M, Herrlich P, Ponta H.

Int J Cancer. 2005 Feb 20;113(5):699-705.

12.

CD44: from adhesion molecules to signalling regulators.

Ponta H, Sherman L, Herrlich PA.

Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45. Review.

PMID:
12511867
13.

Antagonistic signaling pathways regulate alternative splicing of CD44 in T cells.

Weg-Remers S, Ponta H, Herrlich P, König H.

Ann N Y Acad Sci. 2002 Nov;973:112-5. No abstract available.

PMID:
12485845
14.

CD44 is required for two consecutive steps in HGF/c-Met signaling.

Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H.

Genes Dev. 2002 Dec 1;16(23):3074-86.

15.

CD44 variant-specific antibodies trigger hemopoiesis by selective release of cytokines from bone marrow macrophages.

Khaldoyanidi S, Karakhanova S, Sleeman J, Herrlich P, Ponta H.

Blood. 2002 Jun 1;99(11):3955-61.

16.

Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway.

Weg-Remers S, Ponta H, Herrlich P, König H.

EMBO J. 2001 Aug 1;20(15):4194-203.

17.

Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid.

Ahrens T, Sleeman JP, Schempp CM, Howells N, Hofmann M, Ponta H, Herrlich P, Simon JC.

Oncogene. 2001 Jun 7;20(26):3399-408.

18.

The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44.

Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P.

Genes Dev. 2001 Apr 15;15(8):968-80.

19.

Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways.

Matter N, Marx M, Weg-Remers S, Ponta H, Herrlich P, König H.

J Biol Chem. 2000 Nov 10;275(45):35353-60.

20.

CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor.

Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, König H, Weg-Remers S, Ponta H.

Ann N Y Acad Sci. 2000 Jun;910:106-18; discussion 118-20. Review.

PMID:
10911909
21.

CD44 expression and regulation during mammary gland development and function.

Hebbard L, Steffen A, Zawadzki V, Fieber C, Howells N, Moll J, Ponta H, Hofmann M, Sleeman J.

J Cell Sci. 2000 Jul;113 ( Pt 14):2619-30.

22.

Inhibition of MT-450 rat mammary tumour growth by antibodies recognising subtypes of blood group antigen B.

Sleeman JP, Kim U, LePendu J, Howells N, Coquerelle T, Ponta H, Herrlich P.

Oncogene. 1999 Aug 5;18(31):4485-94.

23.
24.

Prognostic value of CD44 variant expression in primary breast cancer.

Foekens JA, Dall P, Klijn JG, Skroch-Angel P, Claassen CJ, Look MP, Ponta H, Van Putten WL, Herrlich P, Henzen-Logmans SC.

Int J Cancer. 1999 Jun 21;84(3):209-15.

25.

CD44 splice variants in draining lymph nodes precede allograft rejection of endocrine cells.

Milde KF, Herrlich P, Ponta H.

J Mol Med (Berl). 1999 Jan;77(1):67-9.

PMID:
9930930
26.

Characterisation of the murine gene encoding the intracellular hyaluronan receptor IHABP (RHAMM).

Fieber C, Plug R, Sleeman J, Dall P, Ponta H, Hofmann M.

Gene. 1999 Jan 8;226(1):41-50.

PMID:
9889313
27.

Problems with RHAMM: a new link between surface adhesion and oncogenesis?

Hofmann M, Assmann V, Fieber C, Sleeman JP, Moll J, Ponta H, Hart IR, Herrlich P.

Cell. 1998 Nov 25;95(5):591-2; author reply 592-3. No abstract available.

28.

CD44 variant isoforms are essential for the function of epidermal Langerhans cells and dendritic cells.

Weiss JM, Renkl AC, Sleeman J, Dittmar H, Termeer CC, Taxis S, Howells N, Schöpf E, Ponta H, Herrlich P, Simon JC.

Cell Adhes Commun. 1998;6(2-3):157-60. Review.

PMID:
9823467
29.

How tumor cells make use of CD44.

Herrlich P, Sleeman J, Wainwright D, König H, Sherman L, Hilberg F, Ponta H.

Cell Adhes Commun. 1998;6(2-3):141-7. Review.

PMID:
9823465
30.

Two different functions for CD44 proteins in human myelopoiesis.

Moll J, Khaldoyanidi S, Sleeman JP, Achtnich M, Preuss I, Ponta H, Herrlich P.

J Clin Invest. 1998 Sep 1;102(5):1024-34.

31.

Activation-dependent modulation of hyaluronate-receptor expression and of hyaluronate-avidity by human monocytes.

Weiss JM, Renkl AC, Ahrens T, Moll J, Mai BH, Denfeld RW, Schöpf E, Ponta H, Herrlich P, Simon JC.

J Invest Dermatol. 1998 Aug;111(2):227-32.

32.

CD44 variant exon v5 encodes a tyrosine that is sulphated.

Sleeman JP, Rahmsdorf U, Steffen A, Ponta H, Herrlich P.

Eur J Biochem. 1998 Jul 1;255(1):74-80.

33.

The CD44 protein family: roles in embryogenesis and tumor progression.

Ponta H, Herrlich P.

Front Biosci. 1998 Jul 1;3:d650-656.

PMID:
28481212
34.
35.

The CD44 protein family.

Ponta H, Wainwright D, Herrlich P.

Int J Biochem Cell Biol. 1998 Mar;30(3):299-305. Review.

PMID:
9611772
36.

Identification of IHABP, a 95 kDa intracellular hyaluronate binding protein.

Hofmann M, Fieber C, Assmann V, Göttlicher M, Sleeman J, Plug R, Howells N, von Stein O, Ponta H, Herrlich P.

J Cell Sci. 1998 Jun;111 ( Pt 12):1673-84.

38.

Variant exons v6 and v7 together expand the repertoire of glycosaminoglycans bound by CD44.

Sleeman JP, Kondo K, Moll J, Ponta H, Herrlich P.

J Biol Chem. 1997 Dec 12;272(50):31837-44.

39.

Interdomain binding mediates tumor growth suppression by the NF2 gene product.

Sherman L, Xu HM, Geist RT, Saporito-Irwin S, Howells N, Ponta H, Herrlich P, Gutmann DH.

Oncogene. 1997 Nov 13;15(20):2505-9.

40.

CD44 expression is aberrant in benign Schwann cell tumors possessing mutations in the neurofibromatosis type 2, but not type 1, gene.

Sherman L, Jacoby LB, Lampe J, Pelton P, Aguzzi A, Herrlich P, Ponta H.

Cancer Res. 1997 Nov 1;57(21):4889-97.

41.

Efficient lysis of CD44v7/8-presenting target cells by genetically engineered cytotoxic T-lymphocytes--a model for immunogene therapy of cervical cancer.

Dall P, Hekele A, Beckmann MW, Bender HG, Herrlich P, Ponta H.

Gynecol Oncol. 1997 Aug;66(2):209-16.

PMID:
9264564
42.

An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function.

Weiss JM, Sleeman J, Renkl AC, Dittmar H, Termeer CC, Taxis S, Howells N, Hofmann M, Köhler G, Schöpf E, Ponta H, Herrlich P, Simon JC.

J Cell Biol. 1997 Jun 2;137(5):1137-47.

43.

Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity.

Sleeman J, Rudy W, Hofmann M, Moll J, Herrlich P, Ponta H.

J Cell Biol. 1996 Nov;135(4):1139-50.

44.

Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera.

Hekele A, Dall P, Moritz D, Wels W, Groner B, Herrlich P, Ponta H.

Int J Cancer. 1996 Oct 9;68(2):232-8.

45.

Trans-acting factors regulate the expression of CD44 splice variants.

Konig H, Moll J, Ponta H, Herrlich P.

EMBO J. 1996 Aug 1;15(15):4030-9.

46.

Expression of CD44 isoforms in human skin cancer.

Simon JC, Heider KH, Dietrich A, Wuttig C, Schöpf E, Adolf GR, Ponta H, Herrlich P.

Eur J Cancer. 1996 Jul;32A(8):1394-400.

PMID:
8869105
47.

Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells.

Sleeman JP, Arming S, Moll JF, Hekele A, Rudy W, Sherman LS, Kreil G, Ponta H, Herrlich P.

Cancer Res. 1996 Jul 1;56(13):3134-41.

48.

A splice variant of CD44 expressed in the rat apical ectodermal ridge contributes to limb outgrowth.

Wainwright D, Sherman L, Sleeman J, Ponta H, Herrlich P.

Ann N Y Acad Sci. 1996 Jun 8;785:345-9. No abstract available.

PMID:
8702177
49.

Increasing incidence of CD44v7/8 epitope expression during uterine cervical carcinogenesis.

Dall P, Hekele A, Ikenberg H, Göppinger A, Bauknecht T, Pfleiderer A, Moll J, Hofmann M, Ponta H, Herrlich P.

Int J Cancer. 1996 Apr 22;69(2):79-85.

50.

Accelerated immune response in transgenic mice expressing rat CD44v4-v7 on T cells.

Moll J, Schmidt A, van der Putten H, Plug R, Ponta H, Herrlich P, Zöller M.

J Immunol. 1996 Mar 15;156(6):2085-94.

PMID:
8690896

Supplemental Content

Support Center